Spots Global Cancer Trial Database for dose limiting toxicity
Every month we try and update this database with for dose limiting toxicity cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Clinical Study of Liposomal Paclitaxel in Chinese Patients | NCT00881101 | Solid Tumor | Liposomal pacli... | 18 Years - 70 Years | Nanjing Sike Pharmaceutical Co., Ltd. | |
| Ispinesib In Combination With Capecitabine In Patients With Solid Tumors | NCT00119171 | Solid Tumor Can... | Ispinesib Capecitabine | 18 Years - | GlaxoSmithKline | |
| Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer | NCT04024800 | Triple-negative... | AE37 Peptide va... Pembrolizumab | 18 Years - | NuGenerex Immuno-Oncology | |
| Temsirolimus in Combination With Metformin in Patients With Advanced Cancers | NCT01529593 | Advanced Cancer... | Temsirolimus Metformin | 14 Years - | M.D. Anderson Cancer Center | |
| Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma | NCT01610570 | Ewing Sarcoma Sarcoma | Mithramycin | 1 Year - | National Institutes of Health Clinical Center (CC) | |
| Ispinesib In Combination With Carboplatin In Patients With Solid Tumors | NCT00136578 | Solid Tumours | SB-715992 carboplatin | 18 Years - | GlaxoSmithKline | |
| Clinical Study of Liposomal Paclitaxel in Chinese Patients | NCT00881101 | Solid Tumor | Liposomal pacli... | 18 Years - 70 Years | Nanjing Sike Pharmaceutical Co., Ltd. | |
| Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors | NCT01352962 | Urethral Neopla... Neoplasms, Uret... Cancer of the U... Urethral Cancer | Gemcitabine Carboplatin Lenalidomide | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With PSMA-positive Prostate Cancer With or Without Prior 177Lu-PSMA Radioligand Therapy. | NCT05983198 | Metastatic Cast... | 225Ac-PSMA-R2 68Ga-PSMA-R2 | 18 Years - | Novartis | |
| A Phase I/II, Open-label, Multi-center Study of [225Ac]Ac-PSMA-R2 in Men With PSMA-positive Prostate Cancer With or Without Prior 177Lu-PSMA Radioligand Therapy. | NCT05983198 | Metastatic Cast... | 225Ac-PSMA-R2 68Ga-PSMA-R2 | 18 Years - | Novartis | |
| Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma | NCT01610570 | Ewing Sarcoma Sarcoma | Mithramycin | 1 Year - | National Institutes of Health Clinical Center (CC) | |
| Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors | NCT01352962 | Urethral Neopla... Neoplasms, Uret... Cancer of the U... Urethral Cancer | Gemcitabine Carboplatin Lenalidomide | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms | NCT00407498 | Neoplasm | P276-00 | 18 Years - | Piramal Enterprises Limited | |
| SB-715992 In Combination With Docetaxel In Patients With Solid Tumors | NCT00169520 | Solid Tumor Can... | docetaxel SB-715992 | 18 Years - | GlaxoSmithKline | |
| SB-743921 In Patients With Solid Tumors | NCT00136513 | Solid Tumor Can... | SB-743921 | 18 Years - | GlaxoSmithKline | |
| Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms | NCT00407498 | Neoplasm | P276-00 | 18 Years - | Piramal Enterprises Limited | |
| Panitumumab in Children With Solid Tumors | NCT00658658 | Solid Tumors | Panitumumab | 1 Year - 17 Years | Amgen | |
| Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma | NCT01610570 | Ewing Sarcoma Sarcoma | Mithramycin | 1 Year - | National Institutes of Health Clinical Center (CC) | |
| Panitumumab in Children With Solid Tumors | NCT00658658 | Solid Tumors | Panitumumab | 1 Year - 17 Years | Amgen | |
| Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors | NCT00420485 | Solid Tumors | gimatecan | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
